Drug class
Targeted antineoplastic; irreversible KRAS G12C inhibitor
Mechanism of action
Irreversibly and covalently binds the mutant cysteine in KRAS G12C, locking the mutant protein in its inactive state and preventing downstream signalling without inhibiting wild-type KRAS.
General use cases
- As monotherapy for adults with KRAS G12C-mutated locally advanced or metastatic non-small-cell lung cancer after at least one prior systemic therapy (accelerated approval; continued approval may depend on confirmatory evidence)
- In combination with cetuximab for adults with KRAS G12C-mutated locally advanced or metastatic colorectal cancer after prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
